<DOC>
	<DOCNO>NCT00003563</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Gadolinium texaphyrin may increase effectiveness radiation therapy make tumor cell sensitive radiation . It yet know whether give gadolinium texaphyrin radiation therapy effective radiation therapy alone treat brain metastasis . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without gadolinium texaphyrin treat patient brain metastasis .</brief_summary>
	<brief_title>Radiation Therapy Plus Gadolinium Texaphyrin Treating Patients With Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety gadolinium texaphyrin administer prior whole brain radiotherapy patient brain metastasis . II . Compare efficacy toxicity whole brain radiotherapy without gadolinium texaphyrin patient . III . Assess quality life patient . OUTLINE : This randomize , two stage , multicenter study . Patients stratify accord RTOG recursive partitioning analysis class ( RPA class 1 v class 2 ) tumor type ( breast v lung v ) . Stage 1 ( lead-in ) : All patient receive gadolinium texaphyrin IV 5-10 minute 10 day receive radiotherapy . Approximately 2-5 hour later , patient undergo whole brain radiotherapy . Stage 2 ( randomization ) : Patients randomize one two treatment arm . Patients arm I undergo whole brain radiotherapy 10 day . Patients arm II receive gadolinium texaphyrin radiotherapy stage 1 . Quality life assess day 10 28 , monthly 5 month , every 3 month thereafter . Patients follow day 28 , monthly 5 month , every 3 month death . PROJECTED ACCRUAL : The lead-in phase accrue least 25-30 patient randomization phase accrue 400 patient ( 200/arm ) 12 month period .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor parenchymal brain metastasis Solitary metastasis eligible refuse surgery surgical resection deem inappropriate No leptomeningeal metastasis subarachnoid spread tumor No small cell lung cancer , germ cell tumor , lymphoma , leukemia No liver metastasis , unless breast cancer No 1 site extracranial metastasis ( multiple bone lung metastases count one site ) , unless breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST ALT great 2 time ULN Renal : Creatinine great 2.0 mg/mL Other : No history porphyria No history G6PD deficiency HIV negative No major medical illnesses No major psychiatric impairment Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No chemotherapy 2 week gadolinium texaphyrin therapy Endocrine therapy : Concurrent hormonal therapy allow Radiotherapy : No prior cranial radiation , include prior stereotactic radiosurgery No plan radiosurgery radiation boost follow whole brain radiotherapy Concurrent radiotherapy allow site , except kidney liver Surgery : No prior subtotal total resection brain metastasis ( except biopsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>tumor metastatic brain</keyword>
</DOC>